KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Short-term Investments: 2009-2017

Historic Short-term Investments for Teva Pharmaceutical Industries (TEVA) over the last 3 years, with Dec 2017 value amounting to $25.0 million.

  • Teva Pharmaceutical Industries' Short-term Investments fell 71.59% to $25.0 million in Q4 2017 from the same period last year, while for Dec 2017 it was $25.0 million, marking a year-over-year decrease of 71.59%. This contributed to the annual value of $25.0 million for FY2017, which is 71.59% down from last year.
  • As of Q4 2017, Teva Pharmaceutical Industries' Short-term Investments stood at $25.0 million, which was down 71.59% from $88.0 million recorded in Q4 2016.
  • Over the past 5 years, Teva Pharmaceutical Industries' Short-term Investments peaked at $105.0 million during Q4 2015, and registered a low of -$366.0 million during Q4 2013.
  • Its 3-year average for Short-term Investments is $72.7 million, with a median of $88.0 million in 2016.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Short-term Investments slumped by 9,250.00% in 2013, and later skyrocketed by 122.40% in 2014.
  • Teva Pharmaceutical Industries' Short-term Investments (Quarterly) stood at -$366.0 million in 2013, then surged by 122.40% to $82.0 million in 2014, then climbed by 28.05% to $105.0 million in 2015, then decreased by 16.19% to $88.0 million in 2016, then slumped by 71.59% to $25.0 million in 2017.
  • Its Short-term Investments stands at $25.0 million for Q4 2017, versus $88.0 million for Q4 2016 and $105.0 million for Q4 2015.